Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas JG, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X, Maurel J. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs. 2013 Dec;31(6):1573-9.
Mangel AW, Fehnel SE. End points in irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2011 Jun 1;5(3):293-5.
Akashi-Ronquest N. The impact of biological preferences on parental investments in children and step-children. Rev Econ Househ. 2009 Mar 1;7(1):59-81.
Van Houtven CH, Wilson MR, Clipp EC. Informal care intensity and caregiver drug utilization. Rev Econ Househ. 2005;3(4):415-33.
Dreyer NA, Loughlin JE, Rothman KJ. Epidemiologic safety surveillance of cellular telephones in the US. Radiat Prot Dosimetry. 1999 Jun;83(1):159-63.